| Document |
Document Title |
|
WO/2024/152435A1 |
Provided are a chimeric antigen receptor containing MSLN, an iNKT cell transducing the chimeric antigen receptor, and the use thereof in treatment of liver cancer, especially intrahepatic cholangiocarcinoma. Utilization of the characteri...
|
|
WO/2024/152787A1 |
The present invention provides a long-acting insulin-Fc fusion protein. The insulin-Fc fusion protein of the present invention has reduced insulin receptor affinity, improved selectivity to auxin receptors, and a prolonged half-life in v...
|
|
WO/2024/154002A1 |
A method for animal protein production in a plant cell is disclosed. The method comprises designing a DNA vector for expression of an animal gene; inserting the DNA vector into the plant cell; grow the cells in defined media under define...
|
|
WO/2024/152259A1 |
The present invention provides a fusion protein having a triple activity and a use thereof. More specifically, the present invention relates to a fusion protein having a triple biological activity of glucagon-like peptide 1 (GLP-1), gluc...
|
|
WO/2024/152578A1 |
Provided are an NKT cell, a derived cell thereof, and the use thereof in preparation of anti-tumor drugs. The NKT cell is named ABL-01 and is preserved in the China Center for Type Culture Collection, the date of deposit being 11 January...
|
|
WO/2024/153050A1 |
The present application relates to a death receptor 5 (DR5) domain variant. The present application also relates to a fusion protein containing the DR5 domain variant. The fusion protein has one or more of the following properties: (1) b...
|
|
WO/2024/153223A1 |
The present application relates to the use of a drug combination in the preparation of a drug. The drug is used for preventing and/or treating systemic lupus erythematosus, and the drug combination comprises an antigen binding protein ta...
|
|
WO/2024/153194A1 |
Provided are activatable interleukin 18 (IL-18) polypeptides comprising: (a) an IL-18 polypeptide (e.g., a wild-type IL-18, an IL-18 variant polypeptide, or a fusion protein comprising the wild-type IL-18 or the IL-18 variant polypeptide...
|
|
WO/2024/152112A1 |
G protein-coupled receptor (GPCR) antibodies coupled to an HD peptide are disclosed, as well as methods of manufacture and uses of said antibodies. The HD peptides may comprise (i) an amino acid sequence of a naturally occurring HD pepti...
|
|
WO/2024/152962A1 |
Provided are an anti-TT3 humanized antibody and the use thereof. The antibody provided has a heavy chain variable region as shown in SEQ ID NO: 1, 2 or 3 and a light chain variable region as shown in SEQ ID NO: 4, 5 or 6. The antibody pr...
|
|
WO/2024/153124A1 |
The present application relates to a modified primary T cell and a preparation method therefor, and a method for culturing NK cells by using the modified primary T cell.
|
|
WO/2024/153235A1 |
The present invention provides fusion proteins of gE and gI (or variants thereof) that can be used for preventing or treating varicella-zoster virus infection, and use of such fusion proteins (or the variants thereof).
|
|
WO/2024/155727A1 |
The invention provides for compositions, systems, and methods for long-range targeted mutagenesis. In particular, the invention provides engineered compositions comprising a programmable nickase configured to introduce a single-strand ni...
|
|
WO/2024/153036A1 |
A CAR molecule, a cell or exosome containing same, and the use thereof. The CAR molecule is a CAR molecule targeting CD19 and/or a CAR molecule targeting CD22. Also disclosed are a nucleic acid encoding the CAR molecule, a recombinant ex...
|
|
WO/2024/152419A1 |
Provided in the present invention are a fusion protein having multiple activities and the use thereof. Particularly, provided in the present invention are a fusion protein having multiple agonist activities for GLP-1, GCG and FGF21 and t...
|
|
WO/2024/153120A1 |
The present invention relates to a mutated PD1 ectodomain fragment and a CAR containing same, and an NK cell. Specifically, the present invention provides a polypeptide, which is the mutated PD1 ectodomain fragment containing an amino ac...
|
|
WO/2024/153211A1 |
Provided herein are fusion polypeptides for degradation of target proteins and methods of use thereof. In some embodiments, the fusion protein includes (1) a non-antibody protein that binds to a target protein, and (2) an E3 ubiquitin li...
|
|
WO/2024/153066A1 |
A mpoxvirus recombinant chimeric antigen, an immunogenic composition, and a use of the recombinant chimeric antigen. The recombinant chimeric antigen comprising a mpoxvirus A35 protein and a mpoxvirus M1 protein can stimulate an immune r...
|
|
WO/2024/152533A1 |
Provided are a recombinant chimeric antigen for a poxvirus, in particular for a Mpoxvirus, a subunit vaccine comprising the recombinant chimeric antigen, and a use thereof. The recombinant chimeric antigen of the present application comp...
|
|
WO/2024/152844A1 |
The present invention relates to the field of medicines, and relates to a protein and vaccine for resisting infection from a SARS-CoV-2 Omicron mutant strain and a subtype thereof. In order to solve the problem of lack of drugs for effec...
|
|
WO/2024/154744A1 |
The present invention relates to fusion proteins or protein complexes comprising a ligand binding moiety fused to a ligand moiety, wherein the ligand binding moiety comprises an IL-12 binding domain and a protease cleavage site that, whe...
|
|
WO/2024/129743A3 |
The present disclosure provides engineered type V nucleases suitable for editing eukaryotic genomic DNA, as well as methods of producing the nucleases, systems comprising the nucleases, as well as methods of using the nucleases and syste...
|
|
WO/2024/149373A1 |
Provided are a nucleic acid molecule, a polypeptide, a protein, a cell, or a system comprising a cytokine, optionally a targeting moiety (e.g., a chimeric antigens receptor), and an anchoring structure that can attach to the surface of a...
|
|
WO/2024/124138A3 |
Provided herein are recombinant polynucleotides comprising a promoter, a ribosome binding site, a sequence encoding a secretion carrier, and a sequence encoding a heterologous protein. Also provided are polypeptides comprising a secretio...
|
|
WO/2024/149039A1 |
The present invention relates to an arginine fluorescent optical probe. Specifically, the present invention provides an arginine-sensitive polypeptide, wherein the arginine-sensitive polypeptide is a variant of an arginine binding protei...
|
|
WO/2024/150786A1 |
The present invention detects, with high sensitivity, a target, on the surface of which exist proteins such as microorganisms and viruses in high density. A first binding molecule and a second binding molecule bonded to a target substa...
|
|
WO/2024/148438A1 |
The present disclosure relates generally to the treatment of Fragile X Syndrome.
|
|
WO/2024/086845A3 |
Described herein are variants of CasPhi2 nucleases with enhanced editing capabilities and methods of use thereof.
|
|
WO/2024/149225A1 |
A humanized CLL1 antibody, a chimeric antigen receptor and the use thereof. The CLL1 antibody or an antigen binding site thereof comprises a heavy chain variable fragment and a light chain variable fragment, wherein the amino acid sequen...
|
|
WO/2017/015637A9 |
Disclosed herein are methods of using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) 9-based epigenomic editing systems for high-throughput screening of regulatory element function.
|
|
WO/2024/102400A3 |
The present disclosure provides surprisingly useful methods of making fusion polypeptides including an immunomodulatory moiety and a metal-hydroxide binding moiety, as well as various related technologies, including and methods of making...
|
|
WO/2024/102587A3 |
The disclosure provides engineered interleukin 18 (IL-18) polypeptides with reduced binding to IL-18 binding protein (IL-18BP) and maintained or improved binding to one or both of IL-18 Receptor alpha (IL-18Rα) and IL-18 Receptor beta (...
|
|
WO/2024/149346A1 |
The present invention relates to a binding protein of immunoregulation protein molecules B7-H3 and the use thereof. Disclosed is a B7-H3-specific antibody, which can specifically bind to B7-H3 to stimulate response of antigen-specific im...
|
|
WO/2024/092258A3 |
Disclosed herein are novel transcription factors for promoting reprogramming of, and/or for direct conversion of, an astrocyte to a neuron. Further provided are polynucleotides encoding the transcription factors, as well as DNA targeting...
|
|
WO/2024/146398A1 |
The present invention relates to a new isolated antibody, an isolated nucleic acid coding the antibody, a chimeric antigen receptor comprising the antibody, a cell comprising the chimeric antigen receptor, and use thereof.
|
|
WO/2024/148324A1 |
GUCY2C T cell antigen coupler (TAC) polypeptides having (i) an antigen-binding domain that binds GUCY2C (e.g., a nanobody), (ii) an antigen-binding domain that binds a protein associated with a TCR complex, and (iii) a T cell receptor si...
|
|
WO/2024/145863A1 |
Immunogenic proteins are provided which have been derived from a strain of HPV which causes or is associated with causing cancer, which are mutated so that they do not cause increased cell proliferation. Within various embodiments of the...
|
|
WO/2024/146379A1 |
This disclosure provides engineered TGFβRII variants, protein constructs, and methods of use thereof.
|
|
WO/2024/146263A1 |
The present invention provides a polypeptide for regulating and controlling the balance of oral microbiota. The sequence of the polypeptide is as shown in SEQ ID NO: 1. The polypeptide can ensure normal physiological activities of oral p...
|
|
WO/2024/146575A1 |
Provided in the present disclosure are a variant of interleukin-2 and the use thereof. Specifically provided in the present disclosure is a variant protein of interleukin-2 (IL-2) or a fragment thereof. Compared with the amino acid seque...
|
|
WO/2024/148337A1 |
The application provides novel viral envelope glycoproteins for pseudotyping viral vectors, novel designs for synthetic antigen receptors (SARs), novel signaling chains for construction of SARs, novel antigen binding domains, and novel m...
|
|
WO/2024/148275A1 |
The present disclosure is directed to leucine zipper-based sorting systems adapted to facilitate the expression and coordination of polypeptide sequences capable of improving the function of CAR T cells. The systems enable the generation...
|
|
WO/2023/196742A9 |
Anti-CD90 antibodies, binding fragments, and uses thereof are described. The provided antibodies and binding fragments can be used to isolate CD90 cells or to target such cells ex vivo or in vivo for a research, a diagnostic, or a therap...
|
|
WO/2024/148303A1 |
Provided herein are compositions, systems, and methods comprising effector proteins, and uses thereof. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the pr...
|
|
WO/2024/140742A1 |
An anti-CD94 antibody and a use thereof. The antibody comprises heavy chain CDR1, CDR2, and CDR3, and light chain CDR1, CDR2, and CDR3, wherein: the amino acid sequences of the heavy chain CDR1, CDR2, and CDR3 respectively have at least ...
|
|
WO/2024/140538A1 |
Provided are systems for strand-specific editing of DNA, including mitochondrial DNA in humans. The systems provided herein comprise a single strand nickase and a deaminase each, or together, associated with a double-stranded DNA binding...
|
|
WO/2024/138897A1 |
Provided are a nanobody targeting BCMA and a chimeric antigen receptor thereof. The nanobody comprises VHH01 and VHH02, and has strong specificity and high affinity for BCMA. A constructed CAR-T cell has high specific killing efficiency ...
|
|
WO/2024/140980A1 |
Provided is a modified cell, comprising a vector which comprises a nucleic acid molecule encoding a chemokine receptor. The cell can also secrete an antigen-binding protein in situ. Further provided are a method for preparing the modifie...
|
|
WO/2024/140710A1 |
Disclosed in the present invention are a synthetic T cell receptor antigen receptor specifically binding to LILRB4 and the use thereof. In the present invention, TCR and CAR are modified by means of targeting the antigen binding fragment...
|
|
WO/2024/145232A1 |
The present disclosure is directed to methods of purifying a dulaglutide composition. For example, the methods comprise loading the dulaglutide composition in-line with a buffer B solution onto a hydrophobic interaction chromatography (H...
|
